RecruitingPHASE1, PHASE2NCT06379789

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Regeneron Pharmaceuticals
Principal Investigator: Clinical Trial Management
Regeneron Pharmaceuticals
Intervention: REGV131(drug)
Enrollment: 130 enrolled
Eligibility: 18 years · MALE
Timeline: 2024 – 2032

Study locations (30)

Orthopaedic Hemophilia Treatment Center, Los Angeles, California, United States
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
University of California Davis, Sacramento, California, United States
University California San Francisco, San Francisco, California, United States
University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States
Yale HTC, New Haven, Connecticut, United States
University of Florida, Gainesville, Florida, United States
Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders, New Orleans, Louisiana, United States
University of Michigan, Ann Arbor, Michigan, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
Royal Prince Alfred Hospital, Haemophilia Treatment Centre, Camperdown, New South Wales, Australia
University of Alberta Hospital, Edmonton, Alberta, Canada
+15 more locations on ClinicalTrials.gov

Collaborators

Intellia Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06379789 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials